Aakash Desai: ICB Retreatment in NSCLC – Who Benefits?
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn about recent paper by Francesco Cortiula et al., titled “Comparative Efficacy of Immunotherapy-based treatment versus Chemotherapy-only in Patients with Unresectable NSCLC with Disease Progression Post Chemoradiation and Durvalumab” publsihed on European Journal of Cancer.
Authors: Francesco Cortiula, Talia Shentzer Kutiel, Melinda L. Hsu, Lizza E.L. Hendriks, Amin H. Nassar, Mor Moskovitz, So Yeon Kim, Matthew M. Mirsky, Ritujith Jayakrishnan, Martina Bortolotti, Jessica Saddi, Paolo Borghetti, Michelle J. Chung, Andrea Riccardo Filippi, Dirk De Ruysscher, Jair Bar.
“ICB Retreatment in NSCLC: Who Benefits?
- Largest cohort of NSCLC patients retreated with ICB after CRT + durvalumab. Key findings:
- PFS ≥12m on durvalumab? ICB retreatment improved OS (22m vs. 9.8m with chemo, p=0.024).
- PFS <12m? No survival benefit with ICB vs. chemo – huge unmet need!
This data highlights the need for better strategies for patients with early progression. More to do in post-durvalumab space!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023